JAMES A GERAGHTY
CIK 1239746 · Senior Vice President · last filed 2026-07-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$989.1K
Companies
8
Total Filings
100
Lifetime Open-Market Net
-$484.0K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FULC | Director | 90,714 | $3.87 | $351.1K | $91.6K | 9 | 2026-07-02 |
| VYGR | Director | 76,588 | $3.30 | $252.7K | $113.1K | 13 | 2026-06-11 |
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Director | 0 | $13.60 | $0 | $105.7K | 13 | 2024-12-12 |
| Orchard Therapeutics plc (ORTX) Delisted | Director | 0 | $16.70 | $0 | $0 | 5 | 2024-01-24 |
| Aceragen, Inc. (IDRA) Delisted | Director | 7,032 | $7.22 | $50.8K | $817.0K | 25 | 2022-06-27 |
| JUNIPER PHARMACEUTICALS INC (JNP) Delisted | Director | 0 | — | — | $455.0K | 13 | 2018-08-15 |
| GENZ | Senior Vice President | 9,845 | $39.13 | $385.3K | -$2.08M | 7 | 2011-04-06 |
| GTC BIOTHERAPEUTICS INC (GTCB) Delisted | Director | 19,163 | — | — | $8.7K | 15 | 2010-01-05 |
Recent Filings · Page 5 of 10
100 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-08-21 | VYGR | Buy (P) | +3,000 | $54.9K | EDGAR |
| 2018-08-15 | JUNIPER PHARMACEUTICALS INC (JNP) Delisted | Disp (D) | −80,747 | -$928.6K | EDGAR |
| 2018-08-08 | Aceragen, Inc. (IDRA) Delisted | Buy (P) | +10,000 | $55.8K | EDGAR |
| 2018-07-05 | Aceragen, Inc. (IDRA) Delisted | Grant (A) | +8,096 | $10.7K | EDGAR |
| 2018-06-22 | Aceragen, Inc. (IDRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-18 | VYGR | Grant (A) | — | $0 | EDGAR |
| 2018-05-16 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Buy (P) | +10,000 | $57.5K | EDGAR |
| 2018-01-29 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-12-14 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-08-17 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Buy (P) | +10,000 | $48.2K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.